Shin Nippon Biomedical Laboratories, Ltd.

Symbol: 2395.T

JPX

1392

JPY

Market price today

  • 10.3343

    P/E Ratio

  • -0.0844

    PEG Ratio

  • 57.95B

    MRK Cap

  • 0.04%

    DIV Yield

Shin Nippon Biomedical Laboratories, Ltd. (2395-T) Financial Statements

On the chart you can see the default numbers in dynamics for Shin Nippon Biomedical Laboratories, Ltd. (2395.T). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Shin Nippon Biomedical Laboratories, Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004

balance-sheet.row.cash-and-short-term-investments

010533.169977286.5
5249.8
5141.5
5312.7
7447
4942.1
7276.3
9751.8
6787
6717.4
9129.3
10346.7
8926.8
6447.8
7180.7
7696
9000.5

balance-sheet.row.short-term-investments

0-423.6368.155.8
-233.7
-220.3
-1044.1
28.3
24.1
-70.1
27.7
-77.3
111.4
1042.2
710.1
404.4
353.3
160.3
1370.8
1295.2

balance-sheet.row.net-receivables

04760.43501.62954.1
2604.7
1986.8
2708.4
3134.2
3396.1
3449.3
3151.3
2918.7
2650.5
2538.8
2933.5
2737.8
2415.9
2393.7
1616.7
1330.5

balance-sheet.row.inventory

07329.44359.44071.4
4031.7
3600
6439.5
6965.6
7315.4
7592.9
5365.5
4451.7
6083.9
7481.5
7948.8
7824.1
8218.8
6682.1
5808.3
4438

balance-sheet.row.other-current-assets

01276.71276.5468.1
523.7
938.1
829.6
599.1
652.1
692
481.1
332.1
350.9
410.8
553.5
337.8
358.2
453
432.6
290.3

balance-sheet.row.total-current-assets

023899.616134.514780
12409.9
11666.4
15290.1
18145.9
16305.7
19010.5
18749.7
14489.5
15802.8
19560.4
21782.5
19826.5
17440.7
16709.5
15553.6
15059.3

balance-sheet.row.property-plant-equipment-net

018879.313155.812898
13699.7
13686.6
14654.2
17104.6
19893.6
19543.1
19205.1
17097.3
16718.6
17442.4
18409.3
18778.8
17967.2
16048.5
11847.7
8348.3

balance-sheet.row.goodwill

01438.80.30.8
0.4
0.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0260.7212213
194
92
0
371.1
341.6
194.9
206.2
101.7
107.2
157.5
198.9
306.8
327.2
396.2
359.4
332.9

balance-sheet.row.goodwill-and-intangible-assets

01699.4212.3213.8
194.4
92.5
288.8
371.1
341.6
194.9
206.2
101.7
107.2
157.5
198.9
306.8
327.2
396.2
359.4
332.9

balance-sheet.row.long-term-investments

01240486458522
12242
27839
27113.8
19045.3
10417.8
1496.5
1273.6
928.7
545.2
-464.2
-301.8
-108.3
907
1075.7
-90.1
-946.8

balance-sheet.row.tax-assets

0325.81129.6521.6
1.8
11.4
11.4
15.7
1
63.2
71.2
92.2
239.7
513.8
610.7
323.3
442.7
200.6
173.1
137.7

balance-sheet.row.other-non-current-assets

034.235.437
454.5
1033
250
1570.3
1281
244
400.1
285.5
497
1438.1
1199.4
987.4
1018.1
822.4
1864.1
1553.6

balance-sheet.row.total-non-current-assets

033342.623178.222192.4
26592.4
42662.6
42318.3
38107.1
31934.9
21541.8
21156.1
18505.4
18107.6
19087.6
20116.5
20288
20662.1
18543.4
14154.3
9425.6

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

057242.239312.736972.4
39002.3
54329
57608.4
56253
48240.6
40552.4
39905.8
32994.9
33910.4
38648
41898.9
40114.5
38102.8
35252.8
29707.8
24484.9

balance-sheet.row.account-payables

0419.864.695
119.3
36.6
84.6
86.7
152.8
73
57.1
105.2
67.3
122.3
199.9
229.9
210.3
166.2
175.5
145.3

balance-sheet.row.short-term-debt

08923.22942.73486.8
5998.3
11348.2
11523.9
11607.7
10315.7
10679.5
8307.7
9238.2
6381.1
5929.9
5065.2
3494
2270.8
2492.5
1934.9
1930.2

balance-sheet.row.tax-payables

0603.7743.1683.2
502.3
69.3
182.1
175.9
1405
846.9
789.3
623.1
86.5
57.5
194.2
300.7
559.9
323.9
359.7
195.5

balance-sheet.row.long-term-debt-total

09837.56195.69199.2
8924.8
4603.2
7409
11298.4
12004.6
11517.2
13394
13481.5
15186.4
15884.8
16924.2
16365.5
11510.6
10174.7
6513.1
8002.2

Deferred Revenue Non Current

0-1064-68.2-642.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

03009.82685.12317.4
2033.1
2092.7
2307.1
2045.4
2086
2496.2
2142.6
2295.4
1676.1
1720.7
1861
2667.2
2424.8
2791.9
2015
1518.9

balance-sheet.row.total-non-current-liabilities

09871.56215.69217.8
9669.3
8083.6
11389.8
14103.7
12269.8
11583
13459.6
13577
15709.4
16031.3
16932.5
16373.9
11523
10289.6
6641.6
8258.7

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

0357385.8529.3
707.5
708.5
484.7
492.3
602.5
378.1
448.3
405
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

030883.219589.521133.6
22620.4
25851.2
31392.7
33779.6
31765.9
30908.4
29390.7
30211.9
29845.3
30782.6
32099.1
30835.8
25144.5
22788.8
17895.3
17776

balance-sheet.row.preferred-stock

002620.8105.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

09679.19679.19679.1
9679.1
9679.1
9679.1
9679.1
9061.5
9061.5
9061.5
5391.1
5391.1
5391.1
5391.1
5391.1
5391.1
5391.1
5391.1
3352.7

balance-sheet.row.retained-earnings

013766.210196.33854.5
-2489
-10082.6
-12059
-8260.3
-7331.9
-7587.4
-6201.6
-5446.6
-4293.8
-886.6
1005.2
571.1
982.7
485.9
45.2
-144

balance-sheet.row.accumulated-other-comprehensive-income-loss

0460.2-2620.8-105.7
3901.4
18450.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

02306.4-314.32200.9
5196.6
10362.3
28538.6
21032.5
14717.4
8142.6
7573.1
2770.4
2909.2
3302.1
3331.4
3246.6
6498.3
6504.3
6380.8
3503.6

balance-sheet.row.total-stockholders-equity

026211.819561.115734.5
16288.1
28409
26158.7
22451.3
16447
9616.7
10433
2714.8
4006.5
7806.5
9727.7
9208.8
12872.1
12381.2
11817
6712.3

balance-sheet.row.total-liabilities-and-stockholders-equity

057242.239312.736972.4
39002.3
54329
57608.4
56253
48240.6
40552.4
39905.8
32994.9
33910.4
38648
41898.9
40114.5
38102.8
35252.8
29707.8
24484.9

balance-sheet.row.minority-interest

0147.2162104.3
93.8
68.8
57
22.1
27.8
27.2
82.2
68.2
58.7
58.9
72.1
70
86.2
82.8
-4.5
-3.3

balance-sheet.row.total-equity

02635919723.115838.8
16381.8
28477.8
26215.7
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

011980.47080.18286.9
12008.3
27618.7
26069.8
19073.7
10441.9
1426.4
1301.3
851.4
656.6
578
408.3
296.1
1260.2
1236
1280.6
348.5

balance-sheet.row.total-debt

018760.79138.312686.1
14923.1
15951.4
18932.8
22906.1
22320.4
22196.7
21701.7
22719.7
21567.6
21814.7
21989.4
19859.5
13781.4
12667.2
8448
9932.4

balance-sheet.row.net-debt

08227.62509.45455.3
9673.2
10809.9
13620.1
15487.4
17402.3
14920.4
11977.6
15932.7
14961.6
13727.6
12352.8
11337.1
7686.9
5646.8
2122.8
2227.2

Cash Flow Statement

The financial landscape of Shin Nippon Biomedical Laboratories, Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004

cash-flows.row.net-income

07759.68183.34175.6
3062.7
1650.7
-1508
-764.7
3550.3
-398.5
95.5
-511.2
-2861.9
-1138.9
411
199.6
856.1
975.9
575.1
-491.2

cash-flows.row.depreciation-and-amortization

01600.51177.41187.7
1229.2
1361.6
1472.8
1545.8
1592.1
1391.9
1318.4
1374.7
1592.9
1763.4
1938.4
1831.4
1819.5
1304.7
919.9
837

cash-flows.row.deferred-income-tax

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-236.4
0

cash-flows.row.stock-based-compensation

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
36.2
0

cash-flows.row.change-in-working-capital

0-2812.9723.3532
-907.3
1276.9
955.5
551.5
375.8
-1735.8
-847.8
-14.8
135.4
-421.1
-224.2
-422.8
106.5
-1648.2
-605.4
810.7

cash-flows.row.account-receivables

0-937-480-343
-619
-149
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0-968.5-371.1-71.7
-445.3
-424.5
398.3
-70.7
-500.9
-1694.8
-559.8
1833.6
1218.2
-84.3
-73.5
-602.3
-1675.2
-793.9
-1055.6
327.3

cash-flows.row.account-payables

0-268.2-36.7-24.2
82.7
119.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-639.21611.1970.8
74.3
1731.2
557.2
622.2
876.7
-40.9
-288
-1848.4
-1082.7
-336.8
-150.7
179.5
1781.6
-854.4
450.2
483.3

cash-flows.row.other-non-cash-items

0-2543.2-4131.3-1148.5
-366.2
-1396.5
423.9
-2182.5
-8858.1
-1413.7
-2186.2
-758.3
100.4
103.4
-381.7
-739.5
384.3
-183.6
65.6
-92.8

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-4955.7-1614.3-1118
-1230.1
-1099.8
-1018.3
-1015.9
-1808.2
-1468.7
-1745.7
-810.8
-895.7
-957.9
-2158.5
-4070.8
-4671.5
-4927.5
-3968.9
-2029.6

cash-flows.row.acquisitions-net

0-1937.21200.81242.3
-4.6
1500.7
1815.5
91.5
3529.8
84.4
-186.3
0
49.2
-44.5
-42.8
-130.4
0
-106.6
0
-199.9

cash-flows.row.purchases-of-investments

0-1514.3-4194.1-895
-790.4
-9
-18.6
-1
-55.8
-208.4
-340.1
-109.1
-191.7
-204.8
-215.2
-1026.4
-158.2
-80
-995.1
-245.1

cash-flows.row.sales-maturities-of-investments

02532.2266.791.4
496.7
20.3
19.3
509
552.2
17.1
355.3
154
2
133
210.1
1947.2
0
116.4
0
27.3

cash-flows.row.other-investing-activites

0-55.572.3410.6
73.3
22.5
39.9
102.2
-932
482.8
144.3
15.7
29.1
224.7
34.4
477.8
14.4
950.7
184.5
2093.1

cash-flows.row.net-cash-used-for-investing-activites

0-5930.6-4268.5-268.7
-1455.1
434.8
837.8
-314.2
1286
-1092.8
-1772.6
-750.3
-1007.1
-849.5
-2172.1
-2802.6
-4815.3
-4047
-4779.6
-354.2

cash-flows.row.debt-repayment

0-5468.1-3492.3-4598.2
-4166.9
-4707.5
-5892.7
-6657.7
-6650.2
-6707.8
-7199.5
-5781.8
-4952
-4258.3
-3679.3
-2293.1
-2378
-2160.8
-1880.4
-1067.7

cash-flows.row.common-stock-issued

00.200
0
0
0
1227.8
0
7198.7
7218.6
16.9
0.2
517.4
0.2
8429.7
0
0
4040.6
0

cash-flows.row.common-stock-repurchased

0-0.200
0
0
-16.6
0
0
0
6043.7
6437.7
0
0
-190.6
-672.8
0
0
378.8
0

cash-flows.row.dividends-paid

0-2484.4-826.5-206.2
-123.6
0
0
0
0
0
-1.2
-1.2
-103.7
-98.5
-102.6
-203.3
-102.2
-102.1
-77.9
-93.2

cash-flows.row.other-financing-activites

014218.8-593.12333.4
2840.9
1205.9
1684.9
9245
6368
15.8
77.1
0
4676.4
3496.5
5805.2
-10.5
3489.5
6348.4
9.8
5924.1

cash-flows.row.net-cash-used-provided-by-financing-activities

06266.2-4912-2471.1
-1449.6
-3501.6
-4224.3
3815.1
-282.2
506.7
6138.7
671.6
-379.1
-343
1833
5250
1009.3
4085.5
2470.8
4763.2

cash-flows.row.effect-of-forex-changes-on-cash

0311.5496.729.6
-5.1
14.9
-87.5
-152.9
9.3
265.9
372.6
168.6
-79.8
-267.8
13.6
-594.3
-91.4
28.6
400.2
-115.2

cash-flows.row.net-change-in-cash

04648.9-27312036.6
108.5
-159.3
-2129.7
2498.2
-2326.8
-2476.2
2977.4
180.3
-2499.2
-1153.5
1418.1
2721.8
-731
515.7
-1153.6
5573.3

cash-flows.row.cash-at-end-of-period

09197.74548.87279.8
5243.3
5134.7
5294.1
7423.8
4925.6
7252.5
9728.7
6751.2
6570.9
9070.1
10223.6
8805.5
6083.7
6814.7
6299
7452.5

cash-flows.row.cash-at-beginning-of-period

04548.87279.85243.3
5134.7
5294.1
7423.8
4925.6
7252.5
9728.7
6751.2
6570.9
9070.1
10223.6
8805.5
6083.7
6814.7
6299
7452.5
1879.2

cash-flows.row.operating-cash-flow

040045952.84746.7
3018.3
2892.7
1344.3
-849.8
-3339.9
-2156
-1620.1
90.3
-1033.2
306.8
1743.6
868.7
3166.4
448.7
755.1
1063.6

cash-flows.row.capital-expenditure

0-4955.7-1614.3-1118
-1230.1
-1099.8
-1018.3
-1015.9
-1808.2
-1468.7
-1745.7
-810.8
-895.7
-957.9
-2158.5
-4070.8
-4671.5
-4927.5
-3968.9
-2029.6

cash-flows.row.free-cash-flow

0-951.74338.53628.7
1788.1
1792.9
326
-1865.7
-5148.1
-3624.8
-3365.8
-720.5
-1928.9
-651.1
-414.9
-3202.1
-1505.1
-4478.8
-3213.9
-966

Income Statement Row

Shin Nippon Biomedical Laboratories, Ltd.'s revenue saw a change of NaN% compared with the previous period. The gross profit of 2395.T is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004

income-statement-row.row.total-revenue

025090.917748.515110.5
14561.1
15658.7
16600.5
17244.5
14750.1
17835
16926.4
17154.1
15274
17371.9
19050.3
19540.2
19647.2
17289.4
13805.4
12295.7

income-statement-row.row.cost-of-revenue

012044.28061.27556.1
6945.4
9480.9
11396.4
12884.2
12059.1
11882.6
11178.2
12467.2
11978.1
12149.3
12825.3
12703.1
11958.4
10590.1
8417
8261.2

income-statement-row.row.gross-profit

013046.79687.37554.4
7615.7
6177.8
5204.1
4360.2
2691
5952.4
5748.2
4686.8
3295.8
5222.6
6225
6837.1
7688.8
6699.3
5388.4
4034.6

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

015.2191.1211.4
119.7
97.5
38.9
-69.8
168.5
162.4
170.5
195
486.2
389.8
542.1
229.5
176.1
30
-20.3
14.6

income-statement-row.row.operating-expenses

07801.45491.75024.9
5387.5
5348
5901.6
6152.7
6554.4
6588.7
6471.9
6114.9
5563.1
5301.5
5125.1
5523.2
5146.6
4832.2
4003.4
3759.1

income-statement-row.row.cost-and-expenses

019845.713552.912581
12332.8
14828.9
17298
19037
18613.5
18471.3
17650.2
18582.1
17541.2
17450.8
17950.4
18226.2
17105
15422.4
12420.4
12020.3

income-statement-row.row.interest-income

057.48.33
9.3
18.5
9.1
15.1
15.2
4
8.2
4.9
9.5
9.4
12.9
45.5
46.5
58.8
58.5
9.3

income-statement-row.row.interest-expense

0125.1126.6184.9
235
377.8
374
378.1
304.3
289.9
307.5
302.3
309.3
343.4
342.7
283.8
251.6
177.6
177.9
150

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0251439861644
832
890
-810.5
1027.8
7413.8
237.8
819.3
916.8
-594.7
-1060.1
-688.9
-1114.4
-1686.1
-891.2
-809.9
-766.6

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

015.2191.1211.4
119.7
97.5
38.9
-69.8
168.5
162.4
170.5
195
486.2
389.8
542.1
229.5
176.1
30
-20.3
14.6

income-statement-row.row.total-operating-expenses

0251439861644
832
890
-810.5
1027.8
7413.8
237.8
819.3
916.8
-594.7
-1060.1
-688.9
-1114.4
-1686.1
-891.2
-809.9
-766.6

income-statement-row.row.interest-expense

0125.1126.6184.9
235
377.8
374
378.1
304.3
289.9
307.5
302.3
309.3
343.4
342.7
283.8
251.6
177.6
177.9
150

income-statement-row.row.depreciation-and-amortization

01600.51177.41187.7
1229.2
1361.6
1472.8
1545.8
1592.1
1391.9
1318.4
1374.7
1592.9
1763.4
1938.4
1831.4
1819.5
1304.7
919.9
837

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

05245.24195.62529.5
2228.3
829.8
-697.5
-1792.5
-3863.4
-636.3
-723.8
-1428.1
-3048.9
-843.7
343.8
463.9
1585.6
1125.8
772.2
-329

income-statement-row.row.income-before-tax

07759.68183.34175.6
3062.7
1650.7
-1508
-764.7
3550.3
-398.5
95.5
-511.2
-2861.9
-1138.9
411
199.6
856.1
975.9
575.1
-491.2

income-statement-row.row.income-tax-expense

01708.91016.2497.8
414.5
-308.1
2013.2
127.8
903.4
992.4
857.6
651.4
443.1
314.4
-116.6
412.7
264.1
433.6
309.4
-17

income-statement-row.row.net-income

06060.17127.63661.9
2550.4
1950.3
-3555.9
-915.9
2646.1
-1385.7
-755
-1152.9
-3304.1
-1442
534.5
-205.5
599.9
543.8
267.4
-472.4

Frequently Asked Question

What is Shin Nippon Biomedical Laboratories, Ltd. (2395.T) total assets?

Shin Nippon Biomedical Laboratories, Ltd. (2395.T) total assets is 57242205000.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.522.

What is company free cash flow?

The free cash flow is 85.787.

What is enterprise net profit margin?

The net profit margin is 0.206.

What is firm total revenue?

The total revenue is 0.150.

What is Shin Nippon Biomedical Laboratories, Ltd. (2395.T) net profit (net income)?

The net profit (net income) is 6060057000.000.

What is firm total debt?

The total debt is 18760662000.000.

What is operating expences number?

The operating expences are 7801426000.000.

What is company cash figure?

Enretprise cash is 0.000.